Cargando…

Lipid metabolism as a target for cancer drug resistance: progress and prospects

Cancer is the world’s leading cause of human death today, and the treatment process of cancer is highly complex. Chemotherapy and targeted therapy are commonly used in cancer treatment, and the emergence of drug resistance is a significant problem in cancer treatment. Therefore, the mechanism of dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zi’an, Wang, Yueqin, Li, Zeyun, Xue, Wenhua, Hu, Shousen, Kong, Xiangzhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571713/
https://www.ncbi.nlm.nih.gov/pubmed/37841917
http://dx.doi.org/10.3389/fphar.2023.1274335
_version_ 1785120065790672896
author Wang, Zi’an
Wang, Yueqin
Li, Zeyun
Xue, Wenhua
Hu, Shousen
Kong, Xiangzhen
author_facet Wang, Zi’an
Wang, Yueqin
Li, Zeyun
Xue, Wenhua
Hu, Shousen
Kong, Xiangzhen
author_sort Wang, Zi’an
collection PubMed
description Cancer is the world’s leading cause of human death today, and the treatment process of cancer is highly complex. Chemotherapy and targeted therapy are commonly used in cancer treatment, and the emergence of drug resistance is a significant problem in cancer treatment. Therefore, the mechanism of drug resistance during cancer treatment has become a hot issue in current research. A series of studies have found that lipid metabolism is closely related to cancer drug resistance. This paper details the changes of lipid metabolism in drug resistance and how lipid metabolism affects drug resistance. More importantly, most studies have reported that combination therapy may lead to changes in lipid-related metabolic pathways, which may reverse the development of cancer drug resistance and enhance or rescue the sensitivity to therapeutic drugs. This paper summarizes the progress of drug design targeting lipid metabolism in improving drug resistance, and providing new ideas and strategies for future tumor treatment. Therefore, this paper reviews the issues of combining medications with lipid metabolism and drug resistance.
format Online
Article
Text
id pubmed-10571713
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105717132023-10-14 Lipid metabolism as a target for cancer drug resistance: progress and prospects Wang, Zi’an Wang, Yueqin Li, Zeyun Xue, Wenhua Hu, Shousen Kong, Xiangzhen Front Pharmacol Pharmacology Cancer is the world’s leading cause of human death today, and the treatment process of cancer is highly complex. Chemotherapy and targeted therapy are commonly used in cancer treatment, and the emergence of drug resistance is a significant problem in cancer treatment. Therefore, the mechanism of drug resistance during cancer treatment has become a hot issue in current research. A series of studies have found that lipid metabolism is closely related to cancer drug resistance. This paper details the changes of lipid metabolism in drug resistance and how lipid metabolism affects drug resistance. More importantly, most studies have reported that combination therapy may lead to changes in lipid-related metabolic pathways, which may reverse the development of cancer drug resistance and enhance or rescue the sensitivity to therapeutic drugs. This paper summarizes the progress of drug design targeting lipid metabolism in improving drug resistance, and providing new ideas and strategies for future tumor treatment. Therefore, this paper reviews the issues of combining medications with lipid metabolism and drug resistance. Frontiers Media S.A. 2023-09-28 /pmc/articles/PMC10571713/ /pubmed/37841917 http://dx.doi.org/10.3389/fphar.2023.1274335 Text en Copyright © 2023 Wang, Wang, Li, Xue, Hu and Kong. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Wang, Zi’an
Wang, Yueqin
Li, Zeyun
Xue, Wenhua
Hu, Shousen
Kong, Xiangzhen
Lipid metabolism as a target for cancer drug resistance: progress and prospects
title Lipid metabolism as a target for cancer drug resistance: progress and prospects
title_full Lipid metabolism as a target for cancer drug resistance: progress and prospects
title_fullStr Lipid metabolism as a target for cancer drug resistance: progress and prospects
title_full_unstemmed Lipid metabolism as a target for cancer drug resistance: progress and prospects
title_short Lipid metabolism as a target for cancer drug resistance: progress and prospects
title_sort lipid metabolism as a target for cancer drug resistance: progress and prospects
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571713/
https://www.ncbi.nlm.nih.gov/pubmed/37841917
http://dx.doi.org/10.3389/fphar.2023.1274335
work_keys_str_mv AT wangzian lipidmetabolismasatargetforcancerdrugresistanceprogressandprospects
AT wangyueqin lipidmetabolismasatargetforcancerdrugresistanceprogressandprospects
AT lizeyun lipidmetabolismasatargetforcancerdrugresistanceprogressandprospects
AT xuewenhua lipidmetabolismasatargetforcancerdrugresistanceprogressandprospects
AT hushousen lipidmetabolismasatargetforcancerdrugresistanceprogressandprospects
AT kongxiangzhen lipidmetabolismasatargetforcancerdrugresistanceprogressandprospects